Table 1 Patient Characteristics
From: Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
Variable | N (%) or Median (IQR) |
|---|---|
Age (years) | 67.5 (9.75) |
Baseline risk (NCCN) | |
Low | 3 (8.8%) |
Intermediate | 7 (20.6%) |
High | 21 (61.8%) |
Unknown | 3 (8.8%) |
Indication (at first scan) | |
Diagnosis / Primary Staging | 2 (5.9%) |
Biochemical Recurrence | 27 (79.4%) |
Restaging of Metastatic Disease | 5 (14.7%) |
Treatment Naive | 2 (5.9%) |
Primary Therapy | 32 (94.1%) |
Radical Prostatectomy | 22 (64.7%) |
Primary EBRT | 5 (14.7%) |
Brachitherapy | 5 (14.7%) |
Previous Salvage Therapy | 14 (41.2%) |
Salvage EBRT | 13 (38.2%) |
Salvage LND | 1 (2.9%) |
Previous Systemic Therapy | 13 (38.2%) |
ADT | 13 (38.2%) |
Chemotherapy | 1 (2.9%) |
Interval Therapya | 9 (26.5%) |
Local | 6 (17.6%) |
Systemic | 3 (8.8%) |
Time between scans (months) | 22.5 (12.08) |
On ADT at 68Ga-PSMA-11 scan | 8 (23.5%) |
On ADT at 18F-DCFPyL scan | 10 (29.4%) |
PSA at 68Ga-PSMA-11 scan (ng/mL) | 1.9 (4.44) |
PSA at 18F-DCFPyL scan (ng/mL) | 2.0 (3.55) |